Patents by Inventor Andrew Pennell

Andrew Pennell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220299157
    Abstract: A system for mounting an inspection device to a case are provided. The system can include a case including a mounting base configured on a side of the case. The system can also include an adjustable stand removably coupled to the case via the mounting base. The adjustable stand can include a receiving portion removably coupled to the mounting base. The adjustable stand can also include a telescopic structure. The telescopic structure can have a plurality of segments. At least one segment can extend longitudinally from a second segment via at least one adjustment mechanism configured on the second segment. The adjustable stand can also include a device holder removably coupled to the second end of the telescopic structure. The device holder can be configured to removably couple with an inspection device. Apparatus and methods of mounting an inspection device to a case are also provided.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 22, 2022
    Inventors: Andrew Tang, Gerard Frederick Beckhusen, Jeffrey Quesnel, Jason Pennell
  • Patent number: 11448360
    Abstract: A system for mounting an inspection device to a case are provided. The system can include a case including a mounting base configured on a side of the case. The system can also include an adjustable stand removably coupled to the case via the mounting base. The adjustable stand can include a receiving portion removably coupled to the mounting base. The adjustable stand can also include a telescopic structure. The telescopic structure can have a plurality of segments. At least one segment can extend longitudinally from a second segment via at least one adjustment mechanism configured on the second segment. The adjustable stand can also include a device holder removably coupled to the second end of the telescopic structure. The device holder can be configured to removably couple with an inspection device. Apparatus and methods of mounting an inspection device to a case are also provided.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: September 20, 2022
    Assignee: Baker Hughes Holdings LLC
    Inventors: Andrew Tang, Gerard Frederick Beckhusen, Jeffrey Quesnel, Jason Pennell
  • Publication number: 20200211307
    Abstract: A smart-structure that includes a securable occupiable space, access to which is controlled by a controller and a personal mobile computing device of a prospective occupant desiring to occupy the securable occupiable space. In some embodiments, access to the personal occupiable space is controlled by an electronic access-control lock that a prospective occupant can cause to unlock via personal area network (PAN) communications directly between a personal mobile computing device and the controller of the smart-structure. Once within the securable occupiable space, the controller may use an occupancy signal to provide the occupant with temporary control of one or more controllable environmental systems associated with the securable occupiable space. Other interactions between a prospective occupant/occupant, former occupant and the smart-structure are also disclosed.
    Type: Application
    Filed: December 31, 2019
    Publication date: July 2, 2020
    Inventors: Benjamin C. Lanza, Andrew Pennell
  • Patent number: 10364240
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: July 30, 2019
    Assignee: ChemoCentryx. Inc.
    Inventors: Solomon Ungashe, John J. Wright, Andrew Pennell, Zheng Wei, Anita Melikian
  • Patent number: 9890148
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: February 13, 2018
    Assignee: ChemoCentryx, Inc.
    Inventors: Solomon Ungashe, John J. Wright, Andrew Pennell, Zheng Wei, Anita Melikian
  • Publication number: 20170369483
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: September 6, 2017
    Publication date: December 28, 2017
    Applicant: ChemoCentryx, Inc.
    Inventors: Solomon Ungashe, John J. Wright, Andrew Pennell, Zheng Wei, Anita Melikian
  • Publication number: 20150080351
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Inventors: Solomon Ungashe, John J. Wright, Andrew Pennell, Zheng Wei
  • Patent number: 8642808
    Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: February 4, 2014
    Assignee: ChemoCentryx, Inc.
    Inventors: Solomon Ungashe, Zheng Wei, John J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
  • Publication number: 20130267492
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: March 28, 2013
    Publication date: October 10, 2013
    Applicant: ChemoCentryx, Inc.
    Inventors: Solomon Ungashe, John J. Wright, Andrew Pennell, Zheng Wei
  • Patent number: 8211896
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: July 3, 2012
    Assignee: Chemocentryx, Inc.
    Inventors: Solomon Ungashe, Zheng Wei, J. J. Wright, Andrew Pennell
  • Publication number: 20120101097
    Abstract: The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.
    Type: Application
    Filed: March 10, 2011
    Publication date: April 26, 2012
    Inventors: Solomon Ungashe, John Jessen Wright, Andrew Pennell
  • Publication number: 20120014997
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: September 26, 2011
    Publication date: January 19, 2012
    Inventors: Solomon Ungashe, J.J. Wright, Andrew Pennell, Zheng Wei, Anita Melikan
  • Publication number: 20110257183
    Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
    Type: Application
    Filed: April 22, 2011
    Publication date: October 20, 2011
    Inventors: Solomon Ungashe, Zheng Wei, J.J. Wright, Andrew Pennell, Brett Premack, Thomas Schall
  • Publication number: 20110201610
    Abstract: The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.
    Type: Application
    Filed: March 10, 2011
    Publication date: August 18, 2011
    Inventors: Solomon Ungashe, John Jessen Wright, Andrew Pennell
  • Patent number: 7932252
    Abstract: The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: April 26, 2011
    Assignee: ChemoCentryx, Inc.
    Inventors: Solomon Ungashe, John Jessen Wright, Andrew Pennell
  • Publication number: 20110021523
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: October 1, 2010
    Publication date: January 27, 2011
    Applicant: CHEMOCENTRYX, INC.
    Inventors: Solomon Ugashe, Zheng Wei, J.J. Wright, Andrew Pennell
  • Publication number: 20100227902
    Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
    Type: Application
    Filed: May 14, 2010
    Publication date: September 9, 2010
    Applicant: CHEMOCENTRYX, INC.
    Inventors: Solomon Ungashe, Zheng Wei, J. J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
  • Patent number: 7741519
    Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: June 22, 2010
    Assignee: ChemoCentryx, Inc.
    Inventors: Solomon Ungashe, Zheng Wei, John J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
  • Publication number: 20090270616
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: July 7, 2009
    Publication date: October 29, 2009
    Applicant: CHEMOCENTRYX, INC
    Inventors: Solomon Ugashe, Zheng Wei, J.J. Wright, Andrew Pennell
  • Patent number: 7582661
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: September 1, 2009
    Assignee: ChemoCentryx, Inc.
    Inventors: Solomon Ugashe, Zheng Wei, John J. Wright, Andrew Pennell